Download Savaysa


January 8th 2015 FDA approved the release of Savaysa

Used for the treatment of: Atrial fibrillation, deep vein




thrombosis, and pulmonary embolism.
Dosage: The recommended dose of Savaysa is 60 mg tablet taken
orally once daily.
Marketing Information from Manufacturer: “In patients with
atrial fibrillation, anti-clotting drugs lower the risk of stroke by
helping to prevent blood clots from forming in the heart,” said
Norman Stockbridge, M.D., Ph.D., director of the Division of
Cardiovascular and Renal Products in the FDA’s Center for Drug
Evaluation and Research. “It is important to have a variety of these
types of drugs available as options for patients.” A study noted by
the FDA indicated; the trial results showed the higher dose of
Savaysa to be similar to warfarin for the reduction in the risk of
stroke. While warfarin is highly effective in reducing the risk of
stroke in patients with atrial fibrillation, it increases the risk of
bleeding. Savaysa demonstrated significantly less major bleeding
compared to warfarin. As with other FDA-approved anti-clotting
drugs, bleeding, including life-threatening bleeding, is the most
serious risk with Savaysa.
Benefits and Concerns of the Drug: This is additional
anticoagulant medication used for specific patients where warfarin
therapy is a concern or not producing the desired results. A study
does not indicate that this medication is more effective than
warfarin.
Coverage Recommendations: These recommendations are
available to IPC/EvergreenRx clients from their Account Manager or
Clinical Pharmacist.
Please contact us with any questions or comments

Special points of interest

Sa va y sa (s a va ye ’ sah )

Pr em atu r e
D isc on t in u at ion O f
Sa va y sa In cr ea ses Th e
Ri sk O f I sch e m i c Ev en t s

Gen er ic N am e
ed ox ab an
T 636.614.1344
www.ipc-inc.com
A Brown & Brown company